Pelthos Therapeutics Inc. PTHS Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Total Revenue by Business | ||||||
| Commercial operations | $10.67M— | —— | —— | —— | $0— | |
| Research and Development operations | $241K— | —— | —— | —— | $0— | |
| Net loss by Business | ||||||
| Commercial operations | -$10.29M— | —— | —— | —— | $0— | |
| Research and Development operations | $55K— | —— | —— | —— | -$1.97M+1.0% | |
| Total Assets by Business | ||||||
| Commercial operations | $144.28M+11.6% | $129.29M— | —— | —— | —— | |
| Research and Development operations | $1.1M-0.4% | $1.11M— | —— | —— | —— | |
| Total Revenue by Product | ||||||
| License and collaboration revenues | $241K— | —— | —— | —— | $0— | |
| Net product revenues | $10.67M— | —— | —— | —— | $0— | |
| Less: current portion by Product | ||||||
| Amended Sato license | $116K+2.7% | $113K— | —— | —— | —— | |
| Reedy Creek Purchase Agreement | $1.73M-11.8% | $1.96M— | —— | —— | —— | |
| Xepi Royalty Agreement | $156K-31.0% | $226K— | —— | —— | —— | |
| ZELSUVMI Royalty Agreement | $1.4M-9.1% | $1.54M— | —— | —— | —— | |
| Number of patents by Product | ||||||
| Original UNC License Agreement U.S.Patents | 20.0% | 2— | —— | —— | —— | |
| U.S.Patents Covering ZELSUVMI | 140.0% | 14— | —— | —— | —— | |
| UNC License Agreement U.S.Patents | 120.0% | 12— | —— | —— | —— | |
| Convertible fees allocated to royalty by Product | ||||||
| Amended Sato license | $33K— | —— | —— | —— | —— | |
| Reedy Creek Purchase Agreement | $0— | —— | —— | —— | —— | |
| Xepi Royalty Agreement | $64K— | —— | —— | —— | —— | |
| ZELSUVMI Royalty Agreement | $0— | —— | —— | —— | —— | |
| Contractual Obligation by Product | ||||||
| Amended Sato license | $1.15M+2.4% | $1.13M— | —— | $1.1M— | —— | |
| Reedy Creek Purchase Agreement | $21.44M+2.7% | $20.87M— | —— | $19.6M— | —— | |
| Xepi Royalty Agreement | $2.28M+2.5% | $2.22M— | —— | $2.17M— | —— | |
| ZELSUVMI Royalty Agreement | $10.2M+4.4% | $9.77M— | —— | $8.88M— | —— | |
| Contractual Obligation, Liability, Payments Accrued by Product | ||||||
| Amended Sato license | $0— | —— | —— | —— | —— | |
| Reedy Creek Purchase Agreement | $214K— | —— | —— | —— | —— | |
| Xepi Royalty Agreement | $0— | —— | —— | —— | —— | |
| ZELSUVMI Royalty Agreement | $160K— | —— | —— | —— | —— | |
| Interest accretion by Product | ||||||
| Amended Sato license | $27K— | —— | —— | —— | —— | |
| Reedy Creek Purchase Agreement | $781K— | —— | —— | —— | —— | |
| Xepi Royalty Agreement | $55K— | —— | —— | —— | —— | |
| ZELSUVMI Royalty Agreement | $588K— | —— | —— | —— | —— | |
| Contractual obligation, measurement input by Product | ||||||
| Amended Sato license | 52.4%0.0pp | 52.4%— | —— | —— | —— | |
| Channel Products Royalty Agreement | 47.2%0.0pp | 47.2%— | —— | —— | —— | |
| Reedy Creek Purchase Agreement | 85%0.0pp | 85%— | —— | —— | —— | |
| Xepi Royalty Agreement | 95%0.0pp | 95%— | —— | —— | —— | |
| ZELSUVMI Royalty Agreement | 85%0.0pp | 85%— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Pelthos Therapeutics Inc. break its business down?
- Pelthos Therapeutics Inc. (PTHS) reports total revenue by business across 2 parts — Commercial operations and Research and Development operations. Each is extracted from the segment footnotes and tracked over time.
- Where does Pelthos Therapeutics Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Pelthos Therapeutics Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
